Chiral Technologies Inc. has announced the acquisition of Arbor Biosciences.
Chiral Technologies Inc. (Pennsylvania, USA) has announced the acquisition of Arbor Biosciences (Michigan, USA).
Founded in 2006 by University of Michigan Prof. Erdogan Gulari and Dr. Jean-Marie Rouillard, Arbor Biosciences has evolved from producing custom DNA microarrays to generating oligonucleotide pools using proprietary massively parallel DNA synthesis technology.
“This is a very exciting time as we are moving Arbor Biosciences to the next level,” stated Jean-Marie Rouillard, CSO and co-founder at Arbor Biosciences “The additional investments by Chiral will help accelerate our growth and deliver innovative, cost-effective solutions to our clients in the biotechnology and life sciences markets faster than previously planned. It will also open up access to new markets.”
The company primarily produce targeted sequencing panels, which are complemented by their services division. Arbor recently expanded into synthetic biology with a cellâfree expression system using linear DNA as a template for rapid protein expression.
“As we diversify our product portfolio to serve the needs of biopharma, Arbor Biosciences delivers the molecular biology foundation to fuel that growth,” said Joseph Barendt, President of Chiral Technologies, Inc.
Arbor Biosciences will continue to operate at its current location in Ann Arbor as a wholly owned subsidiary of Daicel Corporation and managed by Chiral Technologies, Inc. The entire Arbor Biosciences team will remain in place, including co-founders Gulari and Rouillard.